Current Headlines

  1. BioArctic: U.S. Food And Drug Administration Approves Investigational New Drug Application For ABBV-0805

    BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that AbbVie has received approval from the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for ABBV-0805

  2. Machine Learning Algorithm Helps In The Search For New Drugs

    Researchers have designed a machine learning algorithm for drug discovery which has been shown to be twice as efficient as the industry standard, which could accelerate the process of developing new treatments for disease

  3. FDA Approves Cablivi® (Caplacizumab-Yhdp), The First Nanobody®-Based Medicine, For Adults With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

    The U.S. Food and Drug Administration (FDA) has approved Cablivi®(caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Cablivi is the first FDA approved therapy specifically indicated for the treatment of aTTP

  4. Antidote Therapeutics Announces Collaboration With National Cancer Institute To Develop ATI-1013, A Novel Nicotine-Binding Antibody, For Reducing Lung Cancer In High Risk Smokers

    Antidote Therapeutics, Inc. (ATI) announced today it has entered into a collaboration with the National Cancer Institute (NCI) to further develop its lead compound, ATI-1013, to a successful filing of an Investigational New Drug (IND) application. The scope of the collaboration includes manufacturing process development, IND-enabling pharmacology and toxicology studies, and production of ATI-1013 for use in clinical trials. All program results and materials will be provided to ATI for further development. ATI-1013 is

  5. TamRx Launches To Develop Pipeline Of Immuno-oncology Products For Treatment Of Cancers

    BioMotiv, a drug development accelerator associated with The Harrington Project for Discovery & Development, and researchers from Rutgers, The State University of New Jersey, recently announced the formation of a new biotech start-up, TamRx

  6. Innovent Receives IND Approval Of A Bispecific Antibody (IBI318) By The NMPA

    Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality innovative medicines for the treatment of oncology, autoimmune and other major diseases, today announced that its IND application for IBI318, a recombinant fully human bispecific antibody targeting programmed cell death protein 1 (PD-1) and an undisclosed target for a tumor-associated antigen (TAA), recently has been approved by the National Medical Products Administration (NMPA) to initiate clinical trials in patients with hematological and advanced solid tumors

  7. Moleculin Announces Approval For Third Drug To Commence Clinical Trials

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has received approval to begin clinical trials in Poland for its STAT3 inhibitor, WP1220, for the topical treatment of Cutaneous T-Cell Lymphoma (“CTCL”)

  8. LabRoots Showcases The Advancements In Drug Development & Discovery With 2nd Annual Drug Discovery Virtual Conference

    LabRoots, the leading producer of interactive virtual events for research scientists, clinicians and physicians from around the world, will host the 2019 Drug Discovery Virtual Event on a new, more robust platform, allowing attendees to learn and connect seamlessly on mobile, tablet or desktop devices

  9. Frazier Healthcare Partners Launches Recida Therapeutics To Develop Novel Therapeutics For Serious Antibiotic-Resistant Infections

    Frazier Healthcare Partners today announced the launch of Recida Therapeutics, Inc., a biopharmaceutical company focused on the development of novel therapeutics for serious antibiotic-resistant infections. Recida’s lead program, RC-01, is a novel, IND-stage LpxC inhibitor for the treatment of multidrug-resistant gram-negative infections. Recida has licensed development and commercialization rights to RC-01 from FUJIFILM Toyama Chemical Co. Ltd. for all territories outside Japan. Recida intends to a submit an Investigational New Drug application (IND) for

  10. Atomic-Scale Simulation Of Antiarrhythmic Drug Interaction With Cardiac Cells

    To unravel the mysterious mechanisms of drug potency for the treatment of cardiac arrhythmias, a group of researchers at UC Davis have developed novel simulations that provide insights on vital atomic-scale drug-cardiac cells interactions